XNCR vs. KURA, ZYME, AIMT, MGNX, PRLD, IONS, OGN, BBIO, CYTK, and APLS
Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Kura Oncology (KURA), Zymeworks (ZYME), Aimmune Therapeutics (AIMT), MacroGenics (MGNX), Prelude Therapeutics (PRLD), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), and Apellis Pharmaceuticals (APLS). These companies are all part of the "medical" sector.
Xencor (NASDAQ:XNCR) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership.
Xencor has higher revenue and earnings than Kura Oncology. Xencor is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Xencor received 89 more outperform votes than Kura Oncology when rated by MarketBeat users. Likewise, 72.89% of users gave Xencor an outperform vote while only 69.01% of users gave Kura Oncology an outperform vote.
In the previous week, Xencor had 1 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Xencor and 3 mentions for Kura Oncology. Xencor's average media sentiment score of 1.29 beat Kura Oncology's score of 0.69 indicating that Xencor is being referred to more favorably in the media.
Xencor has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
Kura Oncology has a net margin of 0.00% compared to Xencor's net margin of -82.23%. Xencor's return on equity of -20.29% beat Kura Oncology's return on equity.
Xencor presently has a consensus price target of $35.43, indicating a potential upside of 49.11%. Kura Oncology has a consensus price target of $27.94, indicating a potential upside of 35.55%. Given Xencor's higher possible upside, equities research analysts plainly believe Xencor is more favorable than Kura Oncology.
Summary
Xencor beats Kura Oncology on 9 of the 13 factors compared between the two stocks.
Get Xencor News Delivered to You Automatically
Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
